Wedbush Reiterates “Neutral” Rating for Keros Therapeutics (NASDAQ:KROS)
Keros Therapeutics (NASDAQ:KROS – Get Free Report)‘s stock had its “neutral” rating reiterated by investment analysts at Wedbush in a research note issued on Tuesday,Benzinga reports. They presently have a $15.00 target price on the stock. Wedbush’s target price would suggest a potential upside of 49.40% from the stock’s previous close. Several other equities analysts […]
Keros Therapeutics (NASDAQ:KROS – Get Free Report)‘s stock had its “neutral” rating reiterated by investment analysts at Wedbush in a research note issued on Tuesday,Benzinga reports. They presently have a $15.00 target price on the stock. Wedbush’s target price would suggest a potential upside of 49.40% from the stock’s previous close. Several other equities analysts […]
